Pharmacological Intervention in the Elderly Phase 2 (PIE2)
Long Name: Pharmacological Intervention in the Elderly Phase 2 (PIE2)
PIE-II is a completed randomized controlled blinded trial of 9 months of standard aldosterone antagonist (spironolactone) in elderly patients (mean age 70 years) with chronic heart failure and preserved systolic function. The primary outcome was physical performance, assess by formal staged exercise ergometry test with expired gas analysis for peak VO2, as well as 6 minute walk, and SPPB. The main secondary outcome was quality of life. Mechanistic maeausres were Doppler-Echocardiogram and cardiac MRI for measures of cardiac anatomy and function and vascular stiffness. Body composition was assessed by DEXA and MRI. Skeletal muscle biopsies were obtained in some patients. Blood was stored.